Difference between revisions of "Part:BBa K3714016"
Line 11: Line 11:
 
<partinfo>BBa_K3714016 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K3714016 SequenceAndFeatures</partinfo>
 
<br/>
 
<br/>
−
<center>[[File:K3714001.png]]</center>
+
<center>[[File:K3714016.png]]</center>
−
<center><b>Figure.1 | Verification of biosensor theo-AAG/AAAAA. </b> An in vitro transcription system was employed to test if this biosensor can response theophylline signal. The product was run on a denatured PAGE. </center>
+
<center><b>Figure.1 | Verification of stop oligo. </b>The aptazyme was produced by a T7 <i>in vitro</i> transcription system. Gardiquimod is an inhibitor of the cleavage activity. The product was run on a denatured PAGE. </center>
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Revision as of 12:10, 21 October 2021


Stop oligo

An oligonucleotide designed for inhibit aptazyme activity temporarily by toehold meditated strand displacing (TMSD) reaction. It will denature an aptazyme (BBa_K3714010) by hybridization. Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


K3714016.png
Figure.1 | Verification of stop oligo. The aptazyme was produced by a T7 in vitro transcription system. Gardiquimod is an inhibitor of the cleavage activity. The product was run on a denatured PAGE.